When a recipient receives a genetically modified cell therapy product after HCT, there is a need to continue to capture both HCT and CT outcomes. As of the Summer 2020 release, CIBMTR implemented new functionality to reduce center reporting burden and redundancies when having to report multiple cell therapy and HCT events for a single patient. This process is known as “combined follow-up”.
All applicable follow-up forms will be aligned under the same event date at the appropriate timepoints (i.e. Forms 2450+4100 or 2100+4100). Custom enabling and disabling of duplicate questions will streamline follow-up reporting when a recipient receives infusions for multiple indications with overlapping time periods.
If a recipient receives a genetically modified cell therapy infusion and then receives an HCT, all future events will have combined follow-up rules applied as applicable.
Refer to the elearning Combined Follow-Up: HCT and Cellular Therapy for more detailed information on reporting rules.